Botanix’s Chief Commercial Officer, Howie McKibbon, was interviewed on Ausbiz this week to discuss the positive results from our BTX 1702 Phase 1b/2 clinical trial for rosacea.
Botanix Pharmaceuticals (ASX: BOT) hosted an investor update webinar following the announcement of its acquisition of Sofpironium Bromide, the first and only novel treatment for primary axillary hyperhidrosis. Present on the call was President and Executive Chairman, Vince Ippolito; Executive Director, Matt Callahan; Chief Medical Adviser, Dr Patricia Walker; and Chief Commercial Officer, Howie McKibbon.
Botanix President and Executive Chairman, Vince Ippolito, is a world-leading dermatology executive.
In this video, he explains why today’s announcement of our acquisition of Sofpironium Bromide is such a promising commercial opportunity for Botanix – as the first and only new chemical entity developed for the treatment of primary axillary hyperhidrosis.
Botanix Pharmaceuticals (ASX: BOT) executive chairman Vince Ippolito joins Kerry Stevenson on Small Caps to discuss the company’s acquisition of novel dermatology asset Sofpironium Bromide gel.
Meet Dr Clarence Young, Botanix’s Chief Medical Officer.
Dr Young has spent the past three decades dedicating his professional life to fighting infectious diseases and antimicrobial resistance (AMR), at the highest ranks of corporate advisory in big pharma, industry groups, and for the White House Working Group on Antimicrobial Resistance too.
In this short video, he explains why he is so motivated to reduce the risk of infection for haemodialysis patients, which is central to his role here at Botanix.
Botanix Executive Director, Matt Callahan, visited Melbourne last week and took the time to participate in a boardroom interview with veteran business and biotech journalist, @Tim Boreham.
As part of this conversation, Matt Callahan explains the strategic importance of following the US Food and Drug Administration’s (FDA) clinical development blueprint, as we develop our dermatology and antimicrobial products, and reiterates the value of recruiting a highly experienced team at the helm.
He also explains the meticulous methodology underpinning Botanix’s clinical trial process and how we are moving our late-stage products even closer to large underserved patient cohorts in the world’s largest healthcare markets.
Take a look:
Interested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work?
Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to our leadership team.
The first of these is with Dr Ira Lawrence, a Medical Advisor with more than 30 years of senior leadership experience within the global pharmaceutical and medical device industries.
Watch this short video to hear what Dr Lawrence has to say about the future of dermatology.
Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the 2022 Edison Open House: Global Healthcare virtual event this week.
He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:
“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”
Botanix President and Executive Chairman, Vince Ippolito, was interviewed by Christine Corrado from Proactive’s New York studio yesterday.
Their conversation focused on the recent launch of our BTX 1204A canine study for atopic dermatitis and our BTX 1702 rosacea study in Australia and New Zealand.
In commenting on the potential for the atopic dermatitis study, Vince said:
“A successful outcome for this study could lead to partnering opportunities for Botanix in animal health … a $750m dollar market. As well as back into another Phase2b study in humans for atopic dermatitis.”
Take a look:
Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.